Advertisement

Internal and Emergency Medicine

, Volume 8, Issue 6, pp 547–547 | Cite as

Erratum to: New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures

  • Sergio CoccheriEmail author
  • Donatella Orlando
Erratum
  • 562 Downloads

Erratum to: Intern Emerg Med (2013) 8:115–122 DOI 10.1007/s11739-012-0886-6

The original publication of this article unfortunately contained an error in Table 3. Data of mortality and major bleeding in the last column related to apixaban should be corrected as follow:
 

Dabigatran 110

Dabigatran 150

Rivaroxaban

Apixaban

All strokes + SE

 ∆ versus warfarin

1.6

5.8

3.0

3.3

 NNT

625

172

333

300

Ischemic/unknown stroke

 ∆ versus warfarin

−1.4

2.8

1.2

0.8

 NNT

a

357

833

1250

Mortality (all cause)

 ∆ versus warfarin

3.8

4.9

4.1

4.2

 NNT

263

204

244

238

Major bleeding

 ∆ versus warfarin

6.5

2.5

−2.0

9.6

 NNT

154

400

a

104

Intracranial bleeding

 ∆ versus warfarin

5.1

4.4

2.0

4.7

 NNT

196

227

500

213

Positive figures express advantage in events spared vs warfarin

∆ Absolute differences, NNT number needed to treat to avoid one event in 1000 patients per year, SE systemic embolism

aNNT inappropriate

Copyright information

© SIMI 2013

Authors and Affiliations

  1. 1.Cardiovascular Medicine University of BolognaBolognaItaly
  2. 2.Center of Cardiovascular MedicineBolognaItaly

Personalised recommendations